EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials: Insights from PREFERABLE-EFFECT and CONVINCE

Aniek E M Schouten iD, Geert W J Frederix, Martijn M Stuiver, Felix Fischer, Anouk E Hiensch, Krister Cromm, Bernard Canaud, Giovanni F M Strippoli, Anne M May, Miriam P van der Meulen, PREFERABLE-EFFECT Scientific Committee, and the CONVINCE Scientific Committee

PLOS One · 01.06.2026 · 21 (6) · e0350019

DOI: 10.1371/journal.pone.0350019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 01.06.2026. Verfasst von Aniek E M Schouten und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht Unive…. Hauptthemen laut MEDLINE: Cost-Benefit Analysis. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Multinational clinical trials are increasingly common in the European Economic Area, yet no guideline exists on which EQ-5D value set(s) should be used for health economic evaluations alongside multinational trials. Either a single value set or country-specific value sets can be applied, and previous studies have shown that the choice of value set can impact the estimated utility scores. For the EQ-5D-5L, the impact on European pooled cost-utility analyses has not been established. This study evaluates the impact of EQ-5D-5L value sets on cost-utility outcomes in two multinational trials.

Methods

Data from two multinational randomized controlled trials were used: (i) supervised exercise compared to usual care for patients with metastatic breast cancer (PREFERABLE-EFFECT), (ii) hemodiafiltration compared to hemodialysis for patients with kidney failure (CONVINCE). EQ-5D-5L was assessed at baseline and during follow-up. Utility scores and quality-adjusted life years (QALYs) were calculated with the country-specific value set for each participant, and with the value set of each included country. The probability of cost-effectiveness was estimated using bootstrapping.

Results

Mean assigned utility scores per year alive ranged between 0.762 and 0.889 for PREFERABLE-EFFECT, and 0.673 and 0.806 for CONVINCE. The difference in utility scores is largest when participants report low quality of life. Estimated QALY gains ranged between 0.013 and 0.020 for PREFERABLE-EFFECT and 0.045 and 0.058 for CONVINCE. The maximum difference in probability of cost-effectiveness between the value sets was Δ8.3% at €80,000/QALY in PREFERABLE-EFFECT, and Δ11.1% at €40,000/QALY for CONVINCE.

Conclusions

Choice of value set led to substantial variation in absolute utility scores and QALYs, which may influence cost-utility outcomes. This impact could be greater when an intervention prevents or aids recovery of health conditions associated with low quality of life, or results in large mortality differences. Scenario analyses using multiple value sets should be conducted for multinational trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisHumansQuality-Adjusted Life YearsFemaleQuality of LifeBreast NeoplasmsCost-Effectiveness AnalysisRandomized Controlled Trials as TopicMiddle AgedRenal DialysisSurveys and Questionnaires

Autor:innen und Institutionen

  • Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Digital Transformation in Rehabilitation Care, HAN University of Applied Sciences, Nijmegen, the Netherlands.
  • Division of Psychosocial Research and Epidemiology & Center for Quality of Life, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Center for Patient-Centered Outcomes Research, Department for Psychosomatic Medicine, Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
  • Fresenius Medical Care Deutschland GmbH, Global Medical Office, Bad Homburg, Germany.
  • Department of Psychosomatic Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

ORCID-Profile: Aniek E M Schouten

Zitieren

APA

Schouten, A. E. M., Frederix, G. W. J., Stuiver, M. M., Fischer, F., Hiensch, A. E., Cromm, K., Canaud, B., Strippoli, G. F. M., May, A. M., van der Meulen, M. P., & PREFERABLE-EFFECT Scientific Committee, and the CONVINCE Scientific Committee (2026). Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials: Insights from PREFERABLE-EFFECT and CONVINCE. PLOS One, 21(6), e0350019. https://doi.org/10.1371/journal.pone.0350019

Vancouver

Schouten AEM, Frederix GWJ, Stuiver MM, Fischer F, Hiensch AE, Cromm K, et al. Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials: Insights from PREFERABLE-EFFECT and CONVINCE. PLOS One. 2026;21(6):e0350019. doi:10.1371/journal.pone.0350019

BibTeX
@article{Schouten2026,
  author = {Schouten, Aniek E M and Frederix, Geert W J and Stuiver, Martijn M and Fischer, Felix and Hiensch, Anouk E and Cromm, Krister and Canaud, Bernard and Strippoli, Giovanni F M and May, Anne M and van der Meulen, Miriam P and PREFERABLE-EFFECT Scientific Committee, and the CONVINCE Scientific Committee, PREFERABLE-EFFECT Scientific Committee, and the CONVINCE Scientific Committee},
  title = {Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials: Insights from PREFERABLE-EFFECT and CONVINCE},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {e0350019},
  doi = {10.1371/journal.pone.0350019}
}
Kostenlos starten →